Mangoceuticals, Inc. (NASDAQ:MGRX) Short Interest Update

Mangoceuticals, Inc. (NASDAQ:MGRX) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 1,882,096 shares, a growth of 805.4% from the July 15th total of 207,868 shares. Approximately 13.1% of the company’s stock are sold short. Based on an average daily volume of 49,406,730 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Mangoceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in Mangoceuticals by 35.4% in the 2nd quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock valued at $40,000 after buying an additional 6,928 shares in the last quarter. Virtu Financial LLC bought a new stake in Mangoceuticals in the fourth quarter valued at $25,000. Boothbay Fund Management LLC bought a new stake in Mangoceuticals in the fourth quarter valued at $28,000. Jane Street Group LLC acquired a new position in Mangoceuticals during the fourth quarter worth $35,000. Finally, Ikarian Capital LLC acquired a new position in Mangoceuticals during the fourth quarter worth $102,000. Institutional investors own 56.72% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MGRX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mangoceuticals in a research report on Wednesday, June 24th. Wall Street Zen upgraded shares of Mangoceuticals to a “sell” rating in a research note on Saturday, July 25th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Mangoceuticals Stock Down 8.2%

Shares of MGRX stock traded down $0.05 during trading hours on Tuesday, reaching $0.55. 1,344,309 shares of the company’s stock were exchanged, compared to its average volume of 37,237,344. Mangoceuticals has a fifty-two week low of $0.16 and a fifty-two week high of $2.75. The stock has a market capitalization of $9.37 million, a P/E ratio of -0.37 and a beta of 2.10. The business has a fifty day moving average price of $0.42 and a 200-day moving average price of $0.41.

Mangoceuticals (NASDAQ:MGRX) last issued its quarterly earnings results on Tuesday, May 19th. The company reported ($0.22) earnings per share for the quarter. Mangoceuticals had a negative net margin of 4,639.13% and a negative return on equity of 112.00%. The company had revenue of $0.07 million during the quarter.

About Mangoceuticals

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.